Gilead Profit Tops Expectations Despite Lower COVID Drug Sales, Outlook Raised

Gilead Sciences on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped offset lower sales of its COVID-19 antiviral drug and acquisition expenses.
Reuters Health Information

source https://www.medscape.com/viewarticle/983145?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?